How Long Does Tirzepatide Last in Your System

Why a five-day half-life shapes the whole treatment experience

Pharmacokinetics can feel abstract, but the five-day half-life of tirzepatide has very practical consequences. A half-life is the time it takes for the concentration in your blood to fall by half. With a five-day figure, roughly five half-lives are needed before the drug drops to negligible levels — that works out to about 25 days, or just over three and a half weeks, though most pharmacologists use a conservative five-week estimate to account for individual variation.

This extended duration is by design. Tirzepatide is a large peptide molecule modified to resist the enzymes that would otherwise break it down quickly. The result is a medicine that maintains consistent blood levels across the entire week between injections. When you first start treatment, levels build gradually with each weekly dose until the drug reaches what clinicians call steady state, typically after four to six weeks of regular dosing. During that build-up phase, many people notice the effects intensifying from week to week, which is part of why the starting dose of 2.5 mg exists: the first pen's job is to let your system adjust rather than to produce maximum appetite suppression straight away.

The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed 2,539 adults over 72 weeks and found average body-weight reductions of around 20–21% at the 15 mg dose. Those results reflect what happens after months of sustained therapeutic exposure, not the first few weeks. Understanding the half-life helps set realistic expectations for that early period. For a fuller picture of the trial evidence, the timeline for when Mounjaro starts working goes into more detail.

What happens after you stop: the five-week washout

If you're wondering how long Mounjaro lasts in your system because you're thinking about stopping, surgery is approaching, or you're planning a pregnancy, the five-week washout window is the clinically relevant figure to know. It is an estimate, though, not a guarantee, individual differences in body composition, kidney function and age all influence how quickly any medicine is processed.

Practically, the effects on appetite tend to wane earlier than the drug fully clears. Many people report hunger returning more noticeably within one to two weeks of stopping, even though measurable drug levels persist beyond that. Gastric emptying, which tirzepatide slows as part of its mechanism, also returns toward baseline relatively quickly once doses are missed. This is one reason the anaesthetic guidance matters: NHS England advises that patients tell their healthcare team, including the anaesthetist, that they are taking tirzepatide before any procedure, because slowed gastric emptying raises aspiration risk under sedation. If your surgery is coming up, that conversation with your surgical team should happen well in advance.

For those planning to conceive, the general advice is to stop tirzepatide and allow a washout period before trying, and our guide on how long tirzepatide remains in your system gives a useful breakdown of what the clearance timeline looks like. Tirzepatide is not recommended during pregnancy or breastfeeding. Your prescriber is the right person to work out the timing with you, there is no single figure that suits every situation. If you have broader questions about treatment, the full FAQ section covers many of the scenarios patients ask about most often.

Does knowing the half-life change anything about how to use the medicine?

If you're mid-treatment and feeling uncertain about what happens when you're late with a dose, or wondering whether missing one week matters, it's worth understanding the implication of a long half-life: a single missed dose doesn't cause levels to crash the way a short-acting medicine would. Blood concentrations fall, but slowly. That said, the right guidance on what to do (including how many days late is too late) lives in the Patient Information Leaflet that comes with your pen, and with your prescriber. Tirzepatide is sold in the UK under the brand name Mounjaro; a detailed overview of Mounjaro and how it works explains the dual GIP and GLP-1 mechanism that underlies its longer duration of action compared with earlier single-pathway medicines.

One thing the half-life doesn't tell you is when you'll personally feel results. Clinical response varies considerably. Some people notice appetite changes within the first few injections; for others, the shift becomes clearer as doses increase over several months. If you want a precise answer to how long tirzepatide stays in your system based on factors such as your dose and kidney function, that page walks through the key variables in detail. If the cost of sustained private treatment is part of your thinking, a fair-minded look at how UK prices are structured is on the Mounjaro cost page.

If you're thinking about starting tirzepatide, or want a prescriber to review where you are in a current treatment course, you can check your eligibility with our clinical team. A GPhC-registered prescriber at our pharmacy reads every consultation personally. The NICE appraisal of tirzepatide (TA1026) sets out the clinical evidence base that informs prescribing decisions in the UK.